Table 1 Demographic and clinical characteristics

Sex, n (%)

<0.01

 Male

503 (29)

145 (18)

358 (38)

 Female

1255 (71)

670 (82)

585 (62)

Age group collapsed, n (%)

0.06

 18–64

1108 (63)

533 (65)

575 (61)

 ≥65

650 (37)

282 (35)

368 (39)

Mean age (SD)

60.2 (13)

59.6 (13)

60.6 (13)

0.11

Race, n (%)

0.09

 Asian

18 (1)

8 (1)

10 (1)

 Black

340 (19)

179 (22)

161 (17)

 White

1393 (79)

627 (77)

766 (81)

Median household income, n (%)

0.16

 ≤$49,999

1030 (59)

480 (59)

550 (58)

 $50,000–$69,999

460 (26)

197 (24)

263 (28)

 ≥$70,000

239 (14)

123 (15)

116 (12)

Diagnosis year, n (%)

0.02

 2002–2004

270 (15)

146 (18)

124 (13)

 2005–2007

869 (49)

386 (47)

483 (51)

 2008–2010

619 (35)

283 (35)

336 (36)

Mean length of follow-up, y (SD)

3.1 (3)

3.3 (3)

3.0 (3)

0.03

Cancer type, n (%)

 Breast

839 (48)

533 (65)

306 (32)

<0.01

 Colorectal

233 (13)

84 (10)

149 (16)

<0.01

  Colon

146 (8)

50 (61)

96 (10)

<0.01

  Rectal

87 (5)

34 (4)

53 (6)

0.16

 Lung

485 (28)

117 (14)

368 (39)

<0.01

  Small cell

80 (5)

19 (2)

61 (7)

<0.01

  Non-small cell

405 (23)

98 (12)

307 (33)

<0.01

 Lymphoma

201 (11)

81 (10)

120 (13)

0.07

  Hodgkins

29 (2)

12 (2)

17 (2)

0.59

  Non-Hodgkins

172 (10)

69 (9)

103 (11)

0.08

Distant metastasis, n (%)

384 (22)

99 (12)

285 (30)

<0.01

Any PS within 90 days of diagnosis, n (%)

864 (49)

384 (47)

480 (51)

0.11

 Grade 1: ECOG 0, 1; KPS 80–100^a

747 (87)

350 (91)

397 (83)

<0.01

 Grade 2: ECOG 2; KPS 60–70^a

78 (9)

26 (7)

52 (11)

0.04

 Grade 3: ECOG 3, 4; KPS 10–50^a

39 (5)

8 (2)

31 (7)

<0.01

Distant metastasis, n (%)

513 (29)

120 (15)

393 (42)

<0.01

PS, last observed documentation, n (%)

1249 (71)

553 (68)

696 (74)

<0.01

 Grade 1: ECOG 0, 1; KPS 80–100^a

990 (79)

499 (90)

491 (71)

<0.01

 Grade 2: ECOG 2; KPS 60–70^a

141 (11)

34 (6)

107 (15)

<0.01

 Grade 3: ECOG 3, 4; KPS 10–50^a

118 (9)

20 (4)

98 (14)

<0.01

Hospice services, n (%)

129 (7)

21 (3)

108 (12)

<0.01

First course surgical resection, n (%)

1029 (62)

563 (72)

466 (52)

<0.01

Any chemo and hormonal therapies, n (%)

1410 (80)

595 (73)

815 (86)

<0.01

 Alkylating agents^b

547 (39)

269 (45)

278 (34)

<0.01

 Antimetabolites^b

427 (30)

113 (19)

314 (39)

<0.01

 Antitumor antibiotics^b

452 (32)

223 (38)

229 (28)

<0.01

 Hormone therapy^b

594 (42)

318 (53)

276 (34)

<0.01

 Mitotic inhibitors^b

761 (54)

260 (44)

501 (62)

<0.01

 Platinum agents^b

512 (36)

114 (19)

398 (49)

<0.01

 Targeted therapies^b

375 (27)

124 (21)

251 (31)

<0.01

Other^c

175 (10)

48 (6)

127 (13)

<0.01